

## **African Pooled Procurement Mechanism (APPM)**

### **PROCUREMENT OF ESSENTIAL MEDICINES FOR RMNH (REPRODUCTIVE MATERNAL AND NEWBORN HEALTH)**

#### **FRAMEWORK AGREEMENT(S)**

#### **SPECIFIC PROCUREMENT NOTICE (SPN)**

#### **REQUEST FOR BIDS | (ONE-ENVELOPE BIDDING PROCESS)**

**RFB NO: ACDC/APPM/001/25**

**ISSUED ON: 26TH SEPTEMBER 2025**

#### **Background**

The Africa Centres for Disease Control and Prevention (Africa CDC) is a specialized technical institution of the African Union (AU), established in 2017 to strengthen the continent's capacity to prevent, detect, and respond to disease threats. Headquartered in Addis Ababa, Ethiopia, Africa CDC serves as the continent's public health authority, working with all 55 AU Member States to enhance health security and build resilient health systems. Its mandate covers disease surveillance, emergency preparedness and response, laboratory systems, and workforce development. Africa CDC also plays a central role in coordinating Africa's collective response to epidemics and pandemics, promoting equitable access to vaccines, medicines, and diagnostics, and advancing the AU's vision of health sovereignty and self-reliance. Through initiatives such as the Platform for Harmonized African Health Manufacturing (PHAHM) Africa CDC is shaping a future where the continent is better prepared to manage both current and emerging public health challenges.

At the 37th Ordinary Session of the Assembly of the African Union, held on 18 February 2024, the Heads of State and Government officially decided to establish the African Pooled Procurement

Mechanism (APPM) and directed Africa CDC to implement the modalities for full operationalization of the mechanism immediately, aiming to improve affordability, availability, and equitable access to essential medical supplies across all AU Member States. Africa CDC with the support of development partners, has been working on the design of the Pooled Procurement Mechanism which is designed to take a phased approach with few products identified as a start up phase of the APPM.

In consultation with Member States and Regional Economic Communities (RECs) and through internal consultation the following key categories has been identified for the start up phase of the APPM

SRMNH (Sexual Reproductive Maternal Newborn Health) products: Oxytocin Injection 10 IU/ ml, Carbetocin Injection (Heat-Stable) 100 µg/mL, Amoxicillin Dispersible Tablets 125 mg (scored), Amoxicillin Dispersible Tablets 250 mg (un-scored), Magnesium Sulphate Injection 50 % (10 mL and 2ml ), Misoprostol 200 µg Tablets (Sublingual), Levonorgestrel-Releasing Contraceptive Implant – 2-rod (75 mg LNG per rod, total 150 mg), Clomiphene Citrate Tablets 50 mg, Labetalol Tablets 200 mg, and Zinc Sulfate Dispersible Tablets 20 mg

Medical Counter Measures for priority pathogens (Ebola, Marburg, Cholera, Lassa Fever, Yellow Fever, Mpox, Cholera, influenza (IPC, diagnostics and Therapeutics)

The overall purpose of this Tender is to source quality assured medical counter measures at affordable price to Member States through the African Pool Procurement Mechanism. Africa CDC will sign a nonexclusive Framework Agreement (FA) with successful bidders through a competitive and transparent process

### **Product descriptions**

The below lists of products with their detailed technical specification is provided under Section VII, Schedule of Requirements' of the bidding document.

1. Oxytocin injection 10 IU/ml in 1ml Ampoule Injection
2. Carbetocin 100mcg/1ml (Heat-Stable) IV/IM injection
3. Amoxicillin 125mg Dispersible Tablet
4. Amoxicillin 250mg Dispersible Tablet (scored),
5. Magnesium Sulphate 50% in 10ml Injection
6. Magnesium Sulphate Injection 50 % in 2ml
7. Misoprostol 200 µg Tablets (Sublingual),
8. Levonorgestrel-Releasing Contraceptive Implant – 1-rod (75 mg LNG per rod, total 150 mg),
9. Clomiphene Citrate - 50mg – Tablet
10. Labetalol Tablets 200 mg
11. Zinc Sulfate Dispersible Tablets 20 mg

### **Demand Forecast**

Estimated demand per year for the product is provided under Section VII, Schedule of Requirements, part of the Bidding document. Any quantities outlined in this RFP, are an estimated forecast of the total requirement for the duration of the FA or, if so specified, an estimated forecast for the annual requirement. Any estimates are provided in good faith and will not in any

way be deemed to be a commitment on the part of Africa CDC regarding any quantity for future purchases

### **Framework Agreement**

Africa CDC wishes to enter into non-exclusive FA for the procurement of Goods described in Section VII with the specifications outlined in the schedules contained in the Request for Bids, as required from time to time during the term of the FA. It will be a provision of the FA that Africa CDC will not be committed to purchase any minimum quantity of these goods, unless Africa CDC specifically agrees to do so in the FA. Africa CDC will not be liable for any cost in the event that no purchases are made under any resulting FA. Purchases will be made against Purchase Orders or Call of Contract to be issued by Africa CDC in accordance with the terms and conditions of any resulting FA. Actual quantities to be purchased will be communicated through Purchase order or Call of Contract which may vary from Purchase Order to Purchase Order.

### **Duration**

Framework Agreement shall have a duration of two (2) years from the commencement date specified in the Framework Agreement. The initial term may be extended for a maximum of one (1) additional year, provided that such an extension is duly justified. The justification for any extension shall be limited strictly to public health benefits, such as addressing outbreaks, emergencies, or other critical public health needs.

### **Regulatory Evaluation Tiers – Prioritizing African Regulatory Systems**

To support Africa's regulatory sovereignty and build confidence in regional systems, priority will be given to products reviewed and approved by African regulatory authorities, particularly those recognized as WHO Maturity Level 3 (ML3) or above. The following tiered approach will guide regulatory evaluation within the APPM framework:

- i. Tier 1 – African ML3/ML4 NRAs and REC/AMRH/AMA-Affiliated Joint Decisions  
Products approved through full scientific review by African NRAs at ML3 or ML4, or via joint regulatory mechanisms affiliated with Regional Economic Communities (RECs), African Medicines Regulatory Harmonization (AMRH), or the African Medicines Agency (AMA). This includes approvals for both marketing authorization (MA) and cGMP compliance.  
    ▶ *First-priority consideration .*
- ii. Tier2 – African ML2 NRAs (Transitioning)  
Approvals granted by African NRAs at Maturity Level 2, particularly through joint or abridged reviews. Applicable primarily to medium- and low-risk products, pending product risk classification.  
    ▶ *Considered next if Tier 1 options are unavailable.*
- iii. Tier 3 – WHO PQ or Non-African WHO-Listed Authorities (WLAs)  
Products listed on the WHO Prequalification register or approved by non-African WLAs, such as stringent regulatory authorities recognized by WHO.  
    ▶ *Considered only if no suitable Tier 1 or 2 approvals exist.*
- iv. Tier 4 – APPM Independent QA Unit Review  
Products without approvals under Tiers 1–3 may undergo site audit and dossier review by the APPM's independent quality assurance unit, on a case-by-case basis.

## Bidding

Bidding will be conducted through international competitive procurement using a Request for Bids (RFB) as specified in the African Union Procurement Manual Issued March 2024 and is open to all eligible Bidders as defined in the Procurement Manual.

Interested eligible Bidders may obtain further information from African CDC and inspect the bidding document during office hours from 8.00AM to 5.00PM from Monday to Friday. The bidding document in English may be requested by interested eligible Bidders upon the submission of a written application to the address below. The solicitation document will be sent by email upon request.

Bids must be delivered to the address below on or before **7 November 2025, 2:30PM** Addis Ababa time. Electronic Bidding is not permitted. Late Bids will be rejected. Bids will be publicly opened in the presence of the Bidders' designated representatives and anyone who chooses to attend at the address below at **7 November 2025, 3:00PM**. Addis Ababa time.

**The address(es) referred to above is (are):**  
**Africa Centres for Diseases Control and Prevention,**  
**Administration Directorate**  
**Supply Chain Division**  
**Lafto Square, Haile Garment,**  
**Africa CDC Office, A1 Tower, 4<sup>th</sup> floor, Room No. 408**  
**E-mail: [Tender@afriacdc.org](mailto:Tender@afriacdc.org) and [zemenua@afriacdc.org](mailto:zemenua@afriacdc.org) (Please submit your request for clarification to both emails as per the instruction provided in the Bid Data Sheet)**



Africa CDC is a continental autonomous health agency of the African Union established to support public health initiatives of Member States and strengthen the capacity of their public health institutions to detect, prevent, control and respond quickly and effectively to disease threats.

## Safeguarding Africa's Health

[www.afriacdc.org](http://www.afriacdc.org)

✕ f y @ afriacdc